In English | En español
Questions About Cancer? 1-800-4-CANCER

Clinical Trial Results

Summaries of Newsworthy Clinical Trial Results < Back to Main

Page Options

  • Print This Page
  • Email This Document

Search Trial Results

Prostate Cancer Trial Results

Enzalutamide Improves Survival in Patients with Metastatic Prostate Cancer
(Posted: 06/27/2014) - In an international randomized phase III clinical trial, the hormone therapy enzalutamide (Xtandi®) extended survival in men with metastatic prostate cancer that had progressed during treatment with androgen deprivation therapy. Participants in the trial had not received chemotherapy.

NIH-funded study shows increased survival in men with metastatic prostate cancer who receive chemotherapy when starting hormone therapy
(Posted: 12/05/2013, Updated: 06/01/2014) - Men with hormone-sensitive metastatic prostate cancer who received the chemotherapy drug docetaxel given at the start of standard hormone therapy lived longer than patients who received hormone therapy alone, according to early results from a NIH-supported randomized controlled clinical trial.

Finasteride Reduces the Risk of Low-Grade Prostate Cancer in Men 55 and Older
(Posted: 08/28/2013) - Long-term follow-up results from a phase III trial show that regular use of finasteride (Proscar®) for up to 7 years decreased the risk of low-grade prostate cancer in men age 55 and older compared with that in men who received a placebo. Although high-grade cancers were more common in the finasteride group, the finasteride and placebo groups had similar 15-year overall survival rates.

Radium-223 Improves Survival in Patients with Advanced Prostate Cancer
(Posted: 08/02/2013) - Results from a phase III trial show that radium-223 dichloride (Xofigo®) improves overall survival in men with advanced prostate cancer that has spread to their bones compared with placebo.

Abiraterone Improves Survival in Metastatic Prostate Cancer
(Posted: 07/27/2011, Updated: 12/31/2012) - A multinational phase III trial found that the drug abiraterone acetate prolonged the median survival of patients with metastatic castration-resistant prostate cancer by 4 months compared with patients who received a placebo.

1 2 3 4 5  Next >